Teva Pharmaceutical Industries Ltd.'s first-quarter earnings fell 27 percent, as generic competition, a weaker Japanese yen and other factors dragged down revenue for one of the world's largest generic drugmakers.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.